CN103989820B - Medicament for treating hyperlipidemia - Google Patents
Medicament for treating hyperlipidemia Download PDFInfo
- Publication number
- CN103989820B CN103989820B CN201410269395.5A CN201410269395A CN103989820B CN 103989820 B CN103989820 B CN 103989820B CN 201410269395 A CN201410269395 A CN 201410269395A CN 103989820 B CN103989820 B CN 103989820B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- fine powder
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 title claims description 23
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003608 fece Anatomy 0.000 abstract description 2
- 241000218671 Ephedra Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 240000006023 Trichosanthes kirilowii Species 0.000 abstract 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 abstract 1
- 241000301400 Trogopterus Species 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 235000008113 selfheal Nutrition 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 239000003172 expectorant agent Substances 0.000 description 17
- 230000003419 expectorant effect Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 201000005577 familial hyperlipidemia Diseases 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Abstract
The invention discloses a traditional Chinese medicinal composition for treating hyperlipidemia, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicinal composition is prepared from the following raw materials in parts by weight: 30-60 parts of trogopterus dung, 30-60 parts of rhizoma atractylodis, 12-20 parts of trichosanthes kirilowii maxim, 10-20 parts of medlar, 10-20 parts of salvia miltiorrhiza, 30-60 parts of selfheal, 6-12 parts of cortex lycii radicis, 6-12 parts of ephedra and 20-40 parts of radix bupleuri. The traditional Chinese medicinal composition for treating hyperlipidemia is high in cure rate, small in dosage, low in cost and simple in preparation process, does not have adverse response, and is suitable for popularization.
Description
Technical field
The invention belongs to technical field of Chinese medicine, relate to a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, be specifically related to a kind of pharmaceutical composition for the treatment of hyperlipidemia and preparation method thereof.
Background technology
Blood fat refers to the general name of contained lipid in human plasma, it is that the important component part blood fat of blood combines with apolipoprotein formation lipoprotein, lipoprotein is dissolved in blood plasma to carry out transporting and metabolism, when lipid metabolism or running abnormal to make in blood plasma one or more lipids higher than time normal (when cholesterol in serum exceedes normal value 230mg/100ml, triglyceride is more than 140mg/100ml, when beta lipoprotein is more than 390 more than mg/100ml), what be namely called is hyperlipemia.Hyperlipemia is commonly encountered diseases, the frequently-occurring disease of middle-aged and elderly people, is cause one of atherosclerotic risk factor, and this disease is often attributed to the category face of " expectorant is turbid ", " the expectorant stasis of blood " by the traditional Chinese medical science.
Current Chinese traditional treatment hyperlipidemia mainly adopts following three sides:
1. function of spleen and stomach regulating eliminating phlegm and removing dampness." the spleen being the source of producing phlegm ", the prosperity and decline of spleen and the turbid generation of expectorant have important relationship.The spleen has the function to transport and transform nutrients and the lucid yang sending up, if the transportation capabilities of spleen are normal, then water Tianjin is able to biochemistry, and diseases caused by retention of fluid expectorant turbid being difficult is gathered; If usually addicted to food delicious food savoury, taste are impaired, its transporting abnormal ascending-descending of QI, and indigestion is precise and tiny, stifling cohesion becomes expectorant to become turbid.As Jing-Yue Complete Works is said: the body fluid of expectorant and people, the institute of water paddy nothing but, but change its just, then body is strong, and battalion defends fills; Just losing it if change, then cacosplanchnia, body fluid loses, and QI and blood " expectorant birth ".The turbid i.e. life of its expectorant, stockpiles in body, stasis sering and cause hyperlipemia.
2. nourishing the liver and kidney soft pulseization is turbid.Liver belonging to Yin in physique and Yang in function, rely on kidney water profit and support money life, liver body obtains it and moistens foster, and irritability bar reaches happy and thin exhibition freely, and QI and blood is gentle, and meridians are unobstructed, is meaning high and level tone and sun is secret.If lose because ferritic is cloudy, the deficiency of YIN can not contain sun, deficiency-fire stirring up, then deficiency of the yin of the liver, or the liver failing to maintain the normal flow of QI, stagnated QI transforming into fire, the cloudy blood of in-fighting, causes YIN fluid deficiency, production of dryness-heat in the interior, channels to lose soft, hot bright body fluid, become expectorant raw turbid.
3. Huatan Zhuyu reinforcing kidney and strengthening resistance.Suffer from the turbid disease of expectorant with the passing of time, contain in cloudy turbid heresy, yang-energy difficulty is stretched, and causes weakness of spleen-YANG eventually and undermines kidney yang.Kidney yang is that yang-energy is basic, insufficiency of kidney-YANG, can not warm spleen soil, and the transportation capabilities of spleen are difficult to normally.The kidney being a water ZANG-organ, main promote the circulation of qi and water, why water liquid can run by compress in vivo, depends on the gasification of kidney.If kidney yang deficiency, QI failing to transform into body fluid, then stop in aqueous vapor, is aggregated into expectorant and becomes turbid.Therefore Zhang Jingyue is said: " change of expectorant is invariably at spleen, and the basis of expectorant is invariably at kidney.Expectorant is turbid is disease, and its property viscous is coagulated puckery, and often can cause through BI-syndrome involved the blood vessels resistance, raw in blood stasis, expectorant is turbid not to be understood with blood stasis knot, mutually transforms, and mutually doublely holds under the arm, makes the state of an illness more numerous and diverse.
Doctor trained in Western medicine achieves larger achievement to the research of hyperlipidemia and treatment, and Western medicine as Statins, fibrate etc., but needs long-term prescription, and long-term prescription can cause the side effect such as blood fat knock-on after hepatic and renal function, muscle damage and drug withdrawal mostly.Can be described as index effect very good, but do not effect a permanent cure.Chinese medicine, in the treatment of hyperlipemia, has side effect little, and has fundamentally, regulates the equilibrium between yin and yang of body on the whole, treating both the principal and secondary aspects of a disease, the long-range advantage such as respond well and be subject to the favor of increasing patient.Give full play to the characteristic of differentiation of tcm and the few advantage of herbal toxic effect, application compound Chinese medicinal preparation or single medicinal material treatment hyperlipemia are research emphasis of the present invention.
Summary of the invention
An object of the present invention is to provide the Chinese medicine composition for the treatment of hyperlipidemia that a kind of good effect, cure rate are high, have no side effect.
In order to realize object of the present invention, Chinese medicine composition of the present invention is made up of the raw material of following weight portion:
Oletum Trogopterori 30-60 Rhizoma Atractylodis 30-60 Fructus Trichosanthis 12-20 Fructus Lycii 10-20
Radix Salviae Miltiorrhizae 10-20 Spica Prunellae 30-60 Cortex Lycii 6-12 Herba Ephedrae 6-12
Radix Bupleuri 20-40.
As preferably, Chinese medicine composition of the present invention is made up of the raw material of following weight portion:
Oletum Trogopterori 40 Rhizoma Atractylodis 40 Fructus Trichosanthis 15 Fructus Lycii 15 Radix Salviae Miltiorrhizae 15
Spica Prunellae 60 Cortex Lycii 8 Herba Ephedrae 8 Radix Bupleuri 30.
Fang Zhong: Oletum Trogopterori: property is sweet, temperature, promoting blood circulation to remove blood stasis.Have a pain for trusted subordinate's congestion, dysmenorrhea, blood stasis amenorrhea.Rhizoma Atractylodis: pungent, bitter, temperature.Drying damp and strengthening spleen, expelling wind and cold, improving eyesight.For distension and fullness in the abdomen, have loose bowels, edema, beriberi flaccidity of feet with lamenness, rheumatic arthralgia, anemofrigid cold.Fructus Trichosanthis: sweet, micro-hardship, cold.Clearing away heat and eliminating phlegm, relieving stuffiness of the chest by dispersing aggregation of pathogens, moisturizes laxation.For cough due to lung-heat, the turbid Huang of expectorant is thick, obstruction of qi in the chest and cardialgia, blocked-up chest feeling of fullness, acute mastitis, lung abscess, and acute appendicitis swells and ache, constipation.Fructus Lycii: sweet is flat.Nourishing the liver and kidney, replenishing vital essence to improve eyesight.For asthenia damage of essence, soreness of waist and knee joint, vertigo and tinnitus, interior-heat is quenched one's thirst, blood deficiency and yellow complexion, and blurred vision is failed to understand.Radix Salviae Miltiorrhizae: bitter, is slightly cold.Stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, clear away heart-fire relieving restlessness.For menoxenia, amenorrhea dysmenorrhea, lump in the abdomen, breast ventral spine pain, pyretic arthralgia pain, skin infection swells and ache, dysphoria and insomnia; Hepatosplenomegaly, angina pectoris.Spica Prunellae: pungent, bitter, cold.Relieve inflammation or internal heat, improving eyesight, eliminating stagnation, detumescence.For conjunctival congestion and swelling pain, order pearl nyctalgia, has a headache dizzy, scrofula, goiter, and acute mastitis swells and ache; Thyromegaly, tuberculous lymphadenitis, cyclomastopathy, hypertension.Cortex Lycii: sweet, cold.Removing heat from blood removes and steams, lung heat clearing pathogenic fire reducing.For deficiency of YIN hectic fever, hectic fever due to YIN-deficiency night sweat, cough due to lung-heat, spitting of blood, epistaxis, interior-heat is quenched one's thirst.Herba Ephedrae: pungent, micro-hardship, temperature.Diaphoresis cold expelling, depressed lung-energy dispersing, inducing diuresis to remove edema.For anemofrigid cold, uncomfortable in chestly to breath with cough, edema due to wind pathogen edema; Bronchial asthma.Herba ephedrae nourishing the lung to arrest cough.Be used for table disease to separate, asthma and cough.Radix Bupleuri: bitter, is slightly cold.Reconciling superficies and interior, soothing the liver, yang invigorating.For cold, fever, alternate attack of chill and fever, distending pain in the chest and hypochondrium.Through clinical verification, the present invention's all tastes medical material share can blood fat reducing disappear addiction, the liver and kidney nourishing, invigorate blood circulation and rush down turbid, invigorating middle warmer spleen invigorating, good effect is achieved to the treatment of hyperlipidemia.
Another object of the present invention is to provide a kind of preparation method for the treatment of the Chinese medicine composition of high blood ester disease, comprises the following steps:
1) by recipe quantity, Oletum Trogopterori, Rhizoma Atractylodis, Fructus Trichosanthis, Fructus Lycii, Radix Salviae Miltiorrhizae is got, with 95% alcohol reflux 2-3 time, each 1-2 hour, merge extractive liquid, reclaims ethanol, concentrated extracting solution, vacuum drying, obtain extract, extract is ground into fine powder, cross 100 mesh sieves;
2) by recipe quantity, get Spica Prunellae, Cortex Lycii, Herba Ephedrae, Radix Bupleuri mixing, be dried and crushed into fine powder, cross 100 mesh sieves;
3) by step 1) and step 2) gained fine powder fully mixes, and is prepared into tablet, capsule, granule or oral liquid with pharmaceutically acceptable carrier.
The present invention compared with prior art has the following advantages:
1. Chinese medicine composition consumption of the present invention is few, evident in efficacy, without any side effects.
2. Chinese medicine composition of the present invention is regular dosage form, and preparation technology is simple, instant edible, carries, and can preserve for a long time.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
the preparation of EXAMPLE l capsule
prescription:
Oletum Trogopterori 40g Rhizoma Atractylodis 40g Fructus Trichosanthis 15g Fructus Lycii 15g Radix Salviae Miltiorrhizae 15g
Spica Prunellae 60g Cortex Lycii 8g Herba Ephedrae 8g Radix Bupleuri 30g.
preparation method:
1) by recipe quantity, Oletum Trogopterori, Rhizoma Atractylodis, Fructus Trichosanthis, Fructus Lycii, Radix Salviae Miltiorrhizae is got, with 95% alcohol reflux 2 times, each 2 hours, merge extractive liquid, reclaim ethanol, concentrated extracting solution, vacuum drying, obtains extract, and extract is ground into fine powder, crosses 100 mesh sieves;
2) by recipe quantity, get Spica Prunellae, Cortex Lycii, Herba Ephedrae, Radix Bupleuri mixing, be dried and crushed into fine powder, cross 100 mesh sieves;
3) by step 1) and step 2) gained fine powder fully mixes, and No. 0 Capsules is inserted in sterilizing, obtains capsule of the present invention.
the preparation of embodiment 2 granule
prescription:
Oletum Trogopterori 60g Rhizoma Atractylodis 45g Fructus Trichosanthis 15g Fructus Lycii 12g Radix Salviae Miltiorrhizae 15g
Spica Prunellae 42g Cortex Lycii 9g Herba Ephedrae 9g Radix Bupleuri 24g.
preparation method:
1) by recipe quantity, Oletum Trogopterori, Rhizoma Atractylodis, Fructus Trichosanthis, Fructus Lycii, Radix Salviae Miltiorrhizae is got, with 95% alcohol reflux 2 times, each 2 hours, merge extractive liquid, reclaim ethanol, concentrated extracting solution, vacuum drying, obtains extract, and extract is ground into fine powder, crosses 100 mesh sieves;
2) by recipe quantity, get Spica Prunellae, Cortex Lycii, Herba Ephedrae, Radix Bupleuri mixing, be dried and crushed into fine powder, cross 100 mesh sieves;
3) by step 1) and step 2) gained fine powder fully mixes, and adds suitable amount of sucrose and hydroxypropyl methylcellulose, alcohol granulation, pack and get final product after dry.Every bag of 10g, containing crude drug 2g.
the preparation of embodiment 3 tablet
prescription:
Oletum Trogopterori 40 Rhizoma Atractylodis 30 Fructus Trichosanthis 12 Fructus Lycii 15 Radix Salviae Miltiorrhizae 15
Spica Prunellae 40 Cortex Lycii 8 Herba Ephedrae 8 Radix Bupleuri 30.
preparation method:
1) by recipe quantity, Oletum Trogopterori, Rhizoma Atractylodis, Fructus Trichosanthis, Fructus Lycii, Radix Salviae Miltiorrhizae is got, with 95% alcohol reflux 2 times, each 2 hours, merge extractive liquid, reclaim ethanol, concentrated extracting solution, vacuum drying, obtains extract, and extract is ground into fine powder, crosses 100 mesh sieves;
2) by recipe quantity, get Spica Prunellae, Cortex Lycii, Herba Ephedrae, Radix Bupleuri mixing, be dried and crushed into fine powder, cross 100 mesh sieves;
3) by step 1) and step 2) gained fine powder fully mixes, adds suitable amount of sucrose and hydroxypropyl methylcellulose, alcohol granulation, tabletting, obtain Tablets.
the preparation of embodiment 4 oral liquid
prescription:
Oletum Trogopterori 40g Rhizoma Atractylodis 40g Fructus Trichosanthis 15g Fructus Lycii 15g Radix Salviae Miltiorrhizae 15g
Spica Prunellae 60g Cortex Lycii 8g Herba Ephedrae 8g Radix Bupleuri 30g.
preparation method:
1) by recipe quantity, Oletum Trogopterori, Rhizoma Atractylodis, Fructus Trichosanthis, Fructus Lycii, Radix Salviae Miltiorrhizae is got, with 95% alcohol reflux 2 times, each 2 hours, merge extractive liquid, reclaim ethanol, concentrated extracting solution, vacuum drying, obtains extract, and extract is ground into fine powder, crosses 100 mesh sieves;
2) by recipe quantity, get Spica Prunellae, Cortex Lycii, Herba Ephedrae, Radix Bupleuri mixing, be dried and crushed into fine powder, cross 100 mesh sieves;
3) by step 1) and step 2) gained fine powder fully mixes, adds correctives, dextrin and distilled water, obtain oral liquid of the present invention.
clinical laboratory data:
Chinese medicine composition of the present invention is in June, 2009 to 2014 year bed observation in January hyperlipidemia 266 patient, and clinical report is as follows:
1, physical data
In 266 routine patients, male 162 example, women 106 example, at minimum 28 years old of age, maximum 70 years old, the course of disease was many at 10 months to 10 years, 46.8 years old mean age.
2, diagnostic criteria
With reference to " new Chinese medicine guideline of clinical investigations ":
2.1 Western medicine diagnose standards: in normal diet situation, 2 weeks interior survey for 2 times serum total cholesterol (TC) all >=6.0mmol/L(230mg/dL), or triglyceride (TG) >=1.54mmol/L(140mg/dL), or HDL-C (HDL-C) man≤1.04mmol/L (40mg/dL), female≤1.17mmol/L(45mg/dL) person.
2.2 Standards of Chinese Medical Syndrome Differentiations: dizzy, headache, uncomfortable in chest, face purple lip is dark, spiritlessness and weakness, extremities being not warm, distension and fullness in the abdomen, indigestion and loss of appetite loose stool, soreness of the waist and knees, dimly red tongue or purple dark or have petechia ecchymosis or have that tooth prints, Tai Bai or greasy in vain, deep-thready pulse or heavy.
3, inclusive criteria
Include in: 1. close diagnostic criteria person; 2. 20-70 age, person year; 3. any treatment is not done in February before all morbidity; 4. card belongs to that expectorant is turbid checks or hepatic and renal YIN deficiency person; 5. sign Informed Consent Form during first visit, agree to that accepting Therapeutic Method obeys arranger.
4, exclusion standard
Get rid of: 1. do not meet above-mentioned inclusive criteria person; 2. the serious hepatorenal disease person of concurrent infection disease immune diseases Cancer; 3. the special disease person that other have an impact to blood fat is suffered from; 4. corticosteroid hormone or immunosuppressant person was applied in 12 months.
5, Therapeutic Method
Medicine: capsule prepared by embodiment 1.Each 4-6 grain, every day 2 times 30 days was 1 course for the treatment of.Serve on 3 courses for the treatment of.
6, observation index
Get detection in peripheral blood of patients underwent before and after 6.1 health giving quality observation index treatments, adopt enzyme process to measure TC, TG, HDL-C, LDL-C at full automatic biochemical apparatus.
The general health check-up item inspection of 6.2 safety monitoring index: comprise blood pressure, height, weight, heart rate, heart and lung auscultation, liver,spleen,kidney abdominal touch etc.; Blood, urine, feces are conventional; The heart, Liver and kidney function inspection; Untoward reaction that other may occur is observed, and comprises clinical symptoms, sign, lab testing and the order of severity of observing untoward reaction, record process and method, is used for its safety of objective evaluation.
7, criterion of therapeutical effect
Criterion of therapeutical effect is formulated with reference to " Blood Lipid Abnormality in Chinese Adults guideline of prevention and treatment ".
Cure: clinical symptoms, sign disappear, the every inspection of laboratory recovers normal.
Effective: clinical symptoms, sign disappear substantially, lipids detection reaches following any one person: TC decline >=20%, TG decline >=40%, HDL-C rising >=0.26mmol/L(10mg/dL), TC-HDL-C/HDL-C declines >=20%.
Effective: clinical symptoms, sign all take a favorable turn, lipids detection reaches following any one person: TC declines >=0% but < 20%, TG declines >=20% but < 40%, HDL-C rising >=0.104mmol/L(4mg/dL) but < 0.26mmol/L(10mg/dL), TC-HDL-C/HDL-C declines >=10% but < 20%.
Invalid: symptom, sign and the lipids detection person of being not improved after treatment.
8, statistical method
Data acquisition SPSS13.0 software carries out statistical analysis, measurement data with
represent, before and after treatment, Indexes Comparison adopts t inspection; Enumeration data adopts X
2inspection.P < 0.05 represents that difference has statistical significance.
9, result
Before 9.1 Blood Lipid treatments, indices compares, no significant difference p > 0.05, after treatment, TC, TG, LDL-C all decline, and HDL-C rises, with this group before treatment, difference has statistical significance P < 0.05 to indices.Refer to table 1.Safety indexes period in a medicine, 266 routine patients, without any discomfort, have no untoward reaction.
Front and back Blood Lipid for the treatment of table 1 compares (
) mmol/L
Note: * represents and compares before and after treatment, P P < 0.05.
9.2 efficacy results: in 266 routine patients, cure 184 examples (69.2%), effective 45 examples (16.9%), effective 27 examples (10.1%), and invalid 10 examples (3.8%), total effective rate is 96.2%.
Claims (5)
1. treat a Chinese medicine composition for hyperlipidemia, its spy is being that the raw material by following weight portion is made:
2. Chinese medicine composition according to claim 1, its spy is being that the raw material by following weight portion is made
3. Chinese medicine composition according to claim 1 and 2, is characterized in that: described Chinese medicine composition is peroral dosage form.
4. Chinese medicine composition according to claim 3, is characterized in that: described peroral dosage form is tablet, capsule or granule.
5. the preparation method of Chinese medicine composition as claimed in claim 4, comprises the following steps:
1) by recipe quantity, Oletum Trogopterori, Rhizoma Atractylodis, Fructus Trichosanthis, Fructus Lycii, Radix Salviae Miltiorrhizae is got, with 95% alcohol reflux 2-3 time, each 1-2 hour, merge extractive liquid, reclaims ethanol, concentrated extracting solution, vacuum drying, obtain extract, extract is ground into fine powder, cross 100 mesh sieves;
2) by recipe quantity, get Spica Prunellae, Cortex Lycii, Herba Ephedrae, Radix Bupleuri mixing, be dried and crushed into fine powder, cross 100 mesh sieves;
3) by step 1) and step 2) gained fine powder fully mixes, and is prepared into tablet, capsule or granule with pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410269395.5A CN103989820B (en) | 2014-06-17 | 2014-06-17 | Medicament for treating hyperlipidemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410269395.5A CN103989820B (en) | 2014-06-17 | 2014-06-17 | Medicament for treating hyperlipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103989820A CN103989820A (en) | 2014-08-20 |
| CN103989820B true CN103989820B (en) | 2015-07-08 |
Family
ID=51304320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410269395.5A Expired - Fee Related CN103989820B (en) | 2014-06-17 | 2014-06-17 | Medicament for treating hyperlipidemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103989820B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168323A (en) * | 2015-09-03 | 2015-12-23 | 佛山市朗达信息科技有限公司 | Composition with blood-fat-reducing effect and preparation method of composition |
| CN105663794A (en) * | 2016-04-11 | 2016-06-15 | 烟台市蓝洋之草医药生物科技有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating hyperlipidemia |
| CN105816696A (en) * | 2016-04-11 | 2016-08-03 | 烟台市蓝洋之草医药生物科技有限公司 | Traditional Chinese medicinal composition for treating hyperlipidemia |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853702A (en) * | 2005-04-26 | 2006-11-01 | 杨吉星 | Chinese medicinal preparation for lowering blood sugar, blood fat and blood pressure, improving blood flow and immune and its making method |
| CN102657277A (en) * | 2012-05-29 | 2012-09-12 | 郑小玲 | All natural tri-hypo-effects (hypoglycemic, hypolipaemic and hypotensive effects) tea |
-
2014
- 2014-06-17 CN CN201410269395.5A patent/CN103989820B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103989820A (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102178800B (en) | Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN100490789C (en) | Enteric coated Chinese medicinal capsule for treating cancer and preparation method thereof | |
| CN102772737B (en) | Traditional Chinese medicine composition for treating liver cirrhosis and fibrosis and preparation method thereof | |
| CN101716318B (en) | Traditional Chinese medicine preparation for treating tumor of digestive system | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN103989820B (en) | Medicament for treating hyperlipidemia | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN106039109A (en) | Traditional Chinese medicinal liquor for preventing and treating cold dampness accumulation pattern rheumatoid arthritis | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN104800504A (en) | Traditional Chinese medicine preparation for treating nephritis and preparation method | |
| CN102430009B (en) | Traditional Chinese medicinal composition for treating gastrointestinal disease and preparation method thereof | |
| CN101757288B (en) | One treats gastrointestinal disease Chinese medicine composition and preparation method thereof | |
| CN104225016B (en) | A kind of pharmaceutical composition treating due to weakness of spleen and stomach chronic atrophic gastritis | |
| CN101019981B (en) | Chinese medicine preparation and its preparing process | |
| CN103285284A (en) | Medical composition for treating senile vaginitis | |
| CN105749127A (en) | Pharmaceutic preparation for treating stomach cancer and application thereof | |
| CN102106992B (en) | Chinese medicinal granules for treating non-alcoholic steatohepatitis | |
| CN110101820B (en) | A Chinese medicinal composition for treating obesity | |
| CN102430075B (en) | Traditional Chinese medicinal composition for treating gastrointestinal disease and preparation method thereof | |
| CN105920436A (en) | Medicinal preparation for treating lung cancer and preparation method thereof | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| CN105796886A (en) | Pharmaceutical composition capable of treating chronic constipation | |
| CN102018849A (en) | Traditional Chinese medicine composition for preventing irregular menstruation and preparation method thereof | |
| CN104940492A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHANG HUA Free format text: FORMER OWNER: LIU QINGZHEN Effective date: 20150504 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Hua Inventor after: Hu Xiaoyan Inventor after: Xue Mei Inventor after: Wang Lin Inventor before: Liu Qingzhen |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU QINGZHEN TO: ZHANG HUA HU XIAOYAN XUE MEI WANG LIN Free format text: CORRECT: ADDRESS; FROM: 276000 LINYI, SHANDONG PROVINCE TO: 266000 QINGDAO, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150504 Address after: 266000 Chongqing Middle Road, Licang District, Shandong, China, No. 217, No. Applicant after: Zhang Hua Address before: 276000 No. 56 Industrial Street, Luozhuang District, Shandong, Linyi Applicant before: Liu Qingzhen |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161220 Address after: 266000 Jiaozhou Road, Shandong, China, No. 1, No. Patentee after: Qingdao City-Owned Hospital Address before: 266000 Chongqing Middle Road, Licang District, Shandong, China, No. 217, No. Patentee before: Zhang Hua |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150708 Termination date: 20190617 |